Jubilant Ingrevia Ltd. moves to reshape its capital structure

The 6.30% coupon cannot be determined to be above or below Jubilant Ingrevia’s WACD, because a WACD figure is not reported in the annual or quarterly financial data available here.

• Commercial Paper: Rs 100 Cr at a 6.30% coupon implies annual coupon expense of approximately Rs 6.30 Cr, assuming the full amount remains outstanding for one year. This is a derived figure based on the terms quoted.
• WACD: Not separately reported in the cited annual or quarterly disclosures. The latest consolidated total debt shown for Q1 FY27 was Rs 791.81 Cr ^[1], but that does not provide the debt-rate mix or weighted average interest cost.
• Interpretation: The 6.30% is the marginal coupon on one short-term borrowing instrument. WACD would be a blended measure across commercial paper, working-capital borrowings, term debt, lease liabilities or other interest-bearing instruments, and could also reflect fees and effective-interest adjustments. Therefore, comparing 6.30% directly with an inferred finance-cost-to-debt ratio would not be a clean WACD comparison.

Conclusion: 6.30% is a known instrument-level funding rate, but Jubilant Ingrevia’s reported WACD is not available in the cited filings; hence the spread versus WACD cannot be quantified reliably.

The total sanctioned Commercial Paper limit and resulting utilization percentage cannot be verified from the cited disclosures available here. The retrieved item only mentions a Commercial Paper issuance of Rs 50 Crores (Rs 500 million) and does not state the board-sanctioned ceiling or support the referenced Rs 100 Crores tranche. ^[2]

The calculation is:

`Utilization = Rs 100 Crores / sanctioned limit × 100`

Accordingly, the percentage would be 20.00% only if the sanctioned limit was Rs 500 Crores; that limit is not evidenced in the retrieved disclosure.

6.30% appears broadly market-consistent, but the evidence does not support a precise rating-adjusted spread conclusion. It is modestly above Jubilant Ingrevia’s recent blended debt-cost proxy and 30 bp below the identifiable specialty-chemicals CP datapoint: Himadri Speciality Chemical reportedly issued CP at a fixed 6.60% rate.^[3]

Alignment with Jubilant Ingrevia’s borrowing cost

The company does not separately report the interest rate on its short-term borrowings. Current borrowings were Rs 441.10 Crores in Q2 FY26 and Rs 462.07 Crores in Q4 FY26.^[4] A rough proxy can be calculated using quarterly finance cost divided by period-end consolidated total debt, annualized. This is a blended financing-cost proxy, not a direct CP rate:

Notes: † annualized as finance cost ÷ period-end total debt × 4; this includes all financing costs and uses period-end rather than average debt.

The 6.30% CP yield therefore sits close to the approximately 6.0% proxy seen in Q2 and Q4 FY26, while remaining below the higher Q1 FY27 proxy. The Q1 increase should not automatically be interpreted as a new short-term borrowing rate because the finance-cost line is not disaggregated between CP, bank borrowing, leases, refinancing charges, or other items.

Sector comparison

Himadri’s reported 6.60% CP rate is the closest directly observed sector reference, placing Jubilant Ingrevia’s 6.30% instrument 30 bp below that datapoint.^[3] However, the source does not establish that the two issuers had the same credit rating, issue date, tenor, security structure, or fees. Consequently, the difference cannot be attributed solely to credit quality.

The named peer balance sheets also do not provide a clean rating-matched CP curve:

Analyst read: 6.30% is best characterized as within the observable range for a rated specialty-chemicals short-term instrument, rather than evidence of either unusually cheap or expensive funding. A firmer conclusion would require the CP’s credit rating, issue date, discount or yield convention, arranger fees, and multiple same-tenor CP issuances from rating-matched peers.